Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 665 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less FDA Approves Acalabrutinib with Venetoclax for CLL or SLL No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC MOST POPULAR HGTV Star Hilary Farr Shares Breast Cancer Battle December 16, 2021 A Safer, Better Treatment Option for Some Younger Women with Breast... January 11, 2023 Blind Man Overcomes Life Of Struggles & Becomes An Incredible Woodworker November 23, 2021 ESMO Recommendations on Cancer Care Reflected in Un ECOSOC Ministerial Declaration... August 11, 2025 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΗΠΑΤΟΣ Luspatercept Improves the Rate of RBC Transfusion Independence Compared with Epoetin... Grandparents of children with cancer: “I would never want to go... Kinder and more effective – why childhood cancers need specific treatments
